Vera Therapeutics (VERA) announced the atacicept Biologics License Application for the treatment of adults with immunoglobulin A nephropathy was accepted for Priority Review by the FDA. The BLA, which was submitted using the Accelerated Approval Program, was assigned a PDUFA target action date of July 7, 2026.
Marshall Fordyce, Founder and CEO of Vera Therapeutics, said: "FDA's Priority Review designation reinforces the need for new therapies that can reshape the IgAN treatment landscape. We remain committed to working with the FDA to facilitate a thorough review of the BLA."
In pre-market trading on NasdaqGM, Vera Therapeutics shares are up 23.8 percent to $57.59.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.